3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
40
Everolimus
35
Magnetic Resonance Spectroscopy
15
lanreotide
14
gallium Ga 68 dotatate
13
Temozolomide
13
Octreotide
12
Nivolumab
12
pembrolizumab
11
Capecitabine
11
surufatinib
10
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Sunitinib
8
Specimen Handling
7
Carboplatin
7
telotristat ethyl
6
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Lutetium-177
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Ipilimumab
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Endocrine
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled